MA55794A - Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk - Google Patents

Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk

Info

Publication number
MA55794A
MA55794A MA055794A MA55794A MA55794A MA 55794 A MA55794 A MA 55794A MA 055794 A MA055794 A MA 055794A MA 55794 A MA55794 A MA 55794A MA 55794 A MA55794 A MA 55794A
Authority
MA
Morocco
Prior art keywords
therapy
patients
limited
cell count
count
Prior art date
Application number
MA055794A
Other languages
English (en)
Inventor
Jan Endell
- Rowson Günter Fingerle
Christian Kuffer
Mark Winderlich
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA55794A publication Critical patent/MA55794A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055794A 2019-05-03 2020-05-04 Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk MA55794A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19172495 2019-05-03

Publications (1)

Publication Number Publication Date
MA55794A true MA55794A (fr) 2022-03-09

Family

ID=66647010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055794A MA55794A (fr) 2019-05-03 2020-05-04 Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk

Country Status (15)

Country Link
US (1) US20220242952A1 (fr)
EP (1) EP3962943A1 (fr)
JP (2) JP2022532519A (fr)
KR (1) KR20220007087A (fr)
CN (1) CN114072424A (fr)
AU (1) AU2020267823A1 (fr)
CA (1) CA3137664A1 (fr)
EA (1) EA202193024A1 (fr)
IL (1) IL287203A (fr)
MA (1) MA55794A (fr)
MX (1) MX2021013101A (fr)
MY (1) MY209449A (fr)
PH (1) PH12021552743A1 (fr)
SG (1) SG11202111343TA (fr)
WO (1) WO2020225196A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3337506T (pt) 2015-08-21 2021-09-24 Morphosys Ag Combinações e suas utilizações
HUE054496T2 (hu) 2016-10-28 2021-09-28 Morphosys Ag CD19 elleni ellenanyag kombinálása BCL-2-gátlóval és alkalmazásuk
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2022005031A (es) * 2019-10-31 2022-07-27 Morphosys Ag Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2293632C (fr) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
CA2439410C (fr) 2001-02-27 2011-09-06 William D. Figg Analogues de thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
WO2005016326A2 (fr) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
EP2216342B1 (fr) 2003-07-31 2015-04-22 Immunomedics, Inc. Anticorps anti-CD19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
BRPI0613279A8 (pt) 2005-06-20 2018-05-02 Medarex Inc Anticorpo manoclonal isolado, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-cd19, método para inibir o crescimento de células tumorais expressando cd19, e método para depleção de celulas b num indivíduo
ES2426468T3 (es) 2005-12-30 2013-10-23 Merck Patent Gmbh Anticuerpos anti-CD19 con inmunogenicidad reducida
SI2383297T1 (sl) * 2006-08-14 2013-06-28 Xencor Inc. Optimizirana antitelesa, ki ciljajo cd19
CN103694349A (zh) 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
HUE031533T2 (hu) 2007-10-19 2017-07-28 Seattle Genetics Inc CD19-kötõszerek valamint alkalmazásuk
AU2010215239A1 (en) 2009-02-23 2011-09-15 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011147834A1 (fr) 2010-05-26 2011-12-01 Roche Glycart Ag Anticorps contre cd19 et utilisations associées
EP2409993A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré
EP2409712A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
EP2524929A1 (fr) 2011-05-17 2012-11-21 Sanofi Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B
PL3465214T3 (pl) * 2016-05-30 2021-12-20 Morphosys Ag Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów

Also Published As

Publication number Publication date
MY209449A (en) 2025-07-09
IL287203A (en) 2021-12-01
SG11202111343TA (en) 2021-11-29
JP2022532519A (ja) 2022-07-15
EP3962943A1 (fr) 2022-03-09
AU2020267823A1 (en) 2021-11-11
EA202193024A1 (ru) 2022-02-09
CN114072424A (zh) 2022-02-18
US20220242952A1 (en) 2022-08-04
WO2020225196A1 (fr) 2020-11-12
KR20220007087A (ko) 2022-01-18
CA3137664A1 (fr) 2020-11-12
PH12021552743A1 (en) 2022-07-11
JP2026004466A (ja) 2026-01-14
MX2021013101A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
MA55794A (fr) Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2018012143A (es) Métodos de diagnóstico para la toma de decisiones terapéuticas específicas del paciente en el cuidado del cáncer.
EP3707165A4 (fr) Ciblage de lilrb4 avec des cellules car-t ou car-nk dans le traitement du cancer
BR112018000254A2 (pt) inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
PH12014501844B1 (en) Peptidomimetic macrocycles
SI2435432T2 (sl) Sredstva, ki inducirajo apoptozo, za zdravljenje raka in imunskih in avtoimunskih bolezni
MX2019006188A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
CA144779S (en) Device for performing soft tissue massage
MA38860B1 (fr) Cellule progénitrice immuno-modulatrice (imp)
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
BR112015021423A2 (pt) métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
WO2013093115A3 (fr) Séquences de marqueurs du cancer du sein et utilisation desdites séquences de marqueurs du cancer du sein
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
IL277238A (en) Modified oligonucleotides for use in the treatment of tauopathy
IL286482A (en) Expanded nk cell fractions for transplantation in combination therapy
EP3432714A4 (fr) Traitement du cancer basé sur l'administration d'oligonucléotides par l'intermédiaire de jonctions lacunaires provenant de cellules souches mésenchymateuses humaines (hmsc)
IL289787A (en) Antibody combinations for treatment of cancer in specific patients
IL263394A (en) Methods of activating dysfunctional immune cells and treatment of cancer
EP3989984A4 (fr) Traitement anticancéreux par cellules nk pd-l1 positives
EP3999100C0 (fr) Traitement amélioré avec eyp001
EA201791471A1 (ru) Способы применения антисмысловых олигонуклеотидов smad7
PT3285787T (pt) Tratamento de infeções bacterianas em aquicultura
EP2964237A4 (fr) Méthodes destinées à maintenir une population de cellules thérapeutiques sur le site de traitement chez un sujet ayant besoin d'une thérapie cellulaire
PL4054582T3 (pl) Terapeutyczne kombinacje akalabrutynibu i kapiwasertybu w leczeniu nowotworów z komórek b